Activation of hemostasis during cardiopulmonary bypass and pediatric aprotinin dosage.

[1]  M. Davies,et al.  Prospective, randomized, double-blind study of high-dose aprotinin in pediatric cardiac operations. , 1997, The Annals of thoracic surgery.

[2]  J. Copeland,et al.  Aprotinin for primary coronary artery bypass grafting: a multicenter trial of three dose regimens. , 1996, The Annals of thoracic surgery.

[3]  E. Bove,et al.  The Efficacy and Cost of Aprotinin in Children Undergoing Reoperative Open Heart Surgery , 1996, Anesthesia and analgesia.

[4]  G. von Bernuth,et al.  Influence of low-dose aprotinin on the inflammatory reaction due to cardiopulmonary bypass in children. , 1996, The Annals of thoracic surgery.

[5]  P. Penkoske,et al.  Aprotinin in children undergoing repair of congenital heart defects. , 1995, The Annals of thoracic surgery.

[6]  R. Kalil,et al.  Aprotinin in children undergoing correction of congenital heart defects. A double-blind pilot study. , 1994, The Journal of thoracic and cardiovascular surgery.

[7]  G. Hempelmann,et al.  Influence of aprotinin on the thrombomodulin/protein C system in pediatric cardiac operations. , 1994, The Journal of thoracic and cardiovascular surgery.

[8]  M. Jochum,et al.  Hemostatic activation during cardiopulmonary bypass with different aprotinin dosages in pediatric patients having cardiac operations , 1993 .

[9]  G. Hempelmann,et al.  Comparison of two aprotinin dosage regimens in pediatric patients having cardiac operations. Influence on platelet function and blood loss. , 1993, The Journal of thoracic and cardiovascular surgery.

[10]  Z. Su,et al.  Mechanism of the preserving effect of aprotinin on platelet function and its use in cardiac surgery. , 1993, The Journal of thoracic and cardiovascular surgery.

[11]  B. Furie,et al.  Molecular and cellular biology of blood coagulation. , 1992, The New England journal of medicine.

[12]  G. Ziemer,et al.  Aprotinin in paediatric cardiopulmonary bypass surgery , 1992 .

[13]  J. Soria,et al.  Hemostasis in Patients Undergoing Extracorporeal Circulation: The Effect of Aprotinin (Trasylol) , 1991, Thrombosis and Haemostasis.

[14]  J. Miletich,et al.  Relative Importance of Thrombin Compared With Plasmin‐Mediated Platelet Activation in Response to Plasminogen Activation With Streptokinase , 1991, Circulation.

[15]  J. E. Doran,et al.  Effects of high-dose aprotinin on blood loss, platelet function, fibrinolysis, complement, and renal function after cardiopulmonary bypass. , 1991, The Journal of thoracic and cardiovascular surgery.

[16]  J. Soria,et al.  Temperature dependence of plasmin-induced activation or inhibition of human platelets. , 1991, Blood.

[17]  M. Jochum,et al.  Influence of high-dose aprotinin treatment on blood loss and coagulation patterns in patients undergoing myocardial revascularization. , 1990, Anesthesiology.

[18]  M. Elliott,et al.  Aprotinin in paediatric cardiac surgery , 1990 .

[19]  Boscoe M. Paes,et al.  Development of the Hemostatic System in the Neonate and Young Infant , 1990, The American journal of pediatric hematology/oncology.

[20]  D. Cosgrove,et al.  Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol). , 1989, The Journal of thoracic and cardiovascular surgery.

[21]  K. M. Taylor,et al.  EFFECT OF APROTININ ON NEED FOR BLOOD TRANSFUSION AFTER REPEAT OPEN-HEART SURGERY , 1987, The Lancet.

[22]  R. Mcconn.  The role of chemical mediators in the pathophysiology of acute illness and injury , 1982 .

[23]  D. Hammond,et al.  Hemostasis in cyanotic congenital heart disease. , 1970, The Journal of pediatrics.